Pharmacokinetics of Increased Dose Darunavir During Late Pregnancy and Postpartum
IMPAACT P1026s previously demonstrated that during pregnancy darunavir (DRV) exposure was reduced by 26% compared to postpartum with DRV/ritonavir (RTV) 600/100 mg bid. We hypothesized maternal plasma DRV exposure during pregnancy would increase with DRV/RTV 800/100 mg bid. IMPAACT P1026s is an ongoing, non-blinded study of antiretroviral pharmacokinetics (PK) in pregnant women that includes a…